See more : Orbital Corporation Limited (OEC.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Karyopharm Therapeutics Inc. (KPTI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Karyopharm Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Braskem S.A. (BRKM5.SA) Income Statement Analysis – Financial Results
- Glory Ltd. (GLYYY) Income Statement Analysis – Financial Results
- United Therapeutics Corporation (UTHR) Income Statement Analysis – Financial Results
- Truist Financial Corporation (TFC-PO) Income Statement Analysis – Financial Results
- ABx Group Limited (ABX.AX) Income Statement Analysis – Financial Results
Karyopharm Therapeutics Inc. (KPTI)
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 146.03M | 157.07M | 209.82M | 108.09M | 40.89M | 30.34M | 1.61M | 154.00K | 250.00K | 229.00K | 387.00K | 634.00K | 152.00K |
| Cost of Revenue | 4.94M | 5.21M | 3.40M | 2.71M | 2.41M | 161.37M | 107.27M | 86.94M | 97.74M | 60.13M | 28.45M | 14.10M | 0.00 |
| Gross Profit | 141.09M | 151.86M | 206.42M | 105.38M | 38.49M | -131.04M | -105.67M | -86.78M | -97.49M | -59.90M | -28.07M | -13.46M | 152.00K |
| Gross Profit Ratio | 96.62% | 96.68% | 98.38% | 97.50% | 94.11% | -431.95% | -6,583.68% | -56,353.25% | -38,997.60% | -26,156.33% | -7,251.94% | -2,123.19% | 100.00% |
| Research & Development | 138.75M | 148.66M | 160.84M | 150.81M | 122.34M | 161.37M | 107.27M | 86.94M | 97.74M | 60.13M | 28.45M | 14.10M | 8.62M |
| General & Administrative | 131.88M | 145.40M | 143.85M | 126.42M | 0.00 | 48.85M | 24.87M | 23.95M | 21.58M | 15.95M | 5.89M | 2.43M | 1.84M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 131.88M | 145.40M | 143.85M | 126.42M | 105.42M | 48.85M | 24.87M | 23.95M | 21.58M | 15.95M | 5.89M | 2.43M | 1.84M |
| Other Expenses | 0.00 | -83.00K | -85.00K | 206.00K | -50.00K | -33.00K | -81.00K | 10.00K | -2.00K | -27.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 270.63M | 294.06M | 304.69M | 277.23M | 227.76M | 210.22M | 132.14M | 110.89M | 119.33M | 76.08M | 34.34M | 16.52M | 10.46M |
| Cost & Expenses | 275.57M | 299.28M | 308.09M | 279.94M | 230.17M | 210.22M | 132.14M | 110.89M | 119.33M | 76.08M | 34.34M | 16.52M | 10.46M |
| Interest Income | 10.94M | 2.36M | 582.00K | 2.82M | 5.42M | 4.03M | 1.70M | 1.28M | 897.00K | 97.00K | 3.00K | 2.00K | 0.00 |
| Interest Expense | 23.82M | 25.00M | 26.05M | 27.14M | 15.65M | 2.49M | 0.00 | 0.00 | 0.00 | 1.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 530.00K | 621.00K | 789.00K | 972.00K | 974.00K | 735.00K | 713.00K | 717.00K | 634.00K | 323.00K | 144.00K | 122.00K | 83.00K |
| EBITDA | -118.42M | -139.31M | -96.99M | -167.85M | -182.93M | -175.15M | -128.21M | -108.72M | -118.44M | -75.45M | -33.80M | -15.77M | -10.23M |
| EBITDA Ratio | -81.09% | -89.08% | -46.60% | -156.20% | -449.72% | -579.80% | -8,133.21% | -71,903.90% | -47,630.40% | -33,089.96% | -8,772.61% | -2,486.75% | -6,728.95% |
| Operating Income | -129.54M | -142.20M | -98.27M | -171.85M | -189.28M | -179.88M | -130.54M | -110.73M | -119.08M | -75.85M | -33.95M | -15.89M | -10.31M |
| Operating Income Ratio | -88.71% | -90.53% | -46.84% | -159.00% | -462.85% | -592.97% | -8,133.21% | -71,903.90% | -47,630.40% | -33,120.52% | -8,772.61% | -2,506.31% | -6,783.55% |
| Total Other Income/Expenses | -13.24M | -22.72M | -25.55M | -24.11M | -10.28M | 1.50M | 1.62M | 1.29M | 895.00K | 69.00K | 3.00K | 2.00K | 0.00 |
| Income Before Tax | -142.78M | -164.92M | -123.82M | -195.96M | -199.55M | -178.38M | -128.92M | -109.44M | -118.18M | -75.78M | -33.95M | -15.89M | -10.31M |
| Income Before Tax Ratio | -97.77% | -105.00% | -59.01% | -181.31% | -487.98% | -588.02% | -8,032.46% | -71,063.64% | -47,272.40% | -33,090.39% | -8,771.83% | -2,505.99% | -6,783.55% |
| Income Tax Expense | 323.00K | 369.00K | 268.00K | 309.00K | 40.00K | 26.00K | 63.00K | 139.00K | -895.00K | -69.00K | -3.00K | -2.00K | 0.00 |
| Net Income | -143.10M | -165.29M | -124.09M | -196.27M | -199.59M | -178.41M | -128.98M | -109.58M | -118.18M | -75.78M | -33.95M | -15.89M | -10.31M |
| Net Income Ratio | -97.99% | -105.23% | -59.14% | -181.59% | -488.08% | -588.10% | -8,036.39% | -71,153.90% | -47,272.40% | -33,090.39% | -8,771.83% | -2,505.99% | -6,783.55% |
| EPS | -1.25 | -2.02 | -1.65 | -2.72 | -3.22 | -3.14 | -2.81 | -2.92 | -3.32 | -2.43 | -5.59 | -6.64 | -10.27 |
| EPS Diluted | -1.25 | -2.02 | -1.65 | -2.72 | -3.22 | -3.14 | -2.81 | -2.92 | -3.32 | -2.43 | -5.59 | -6.64 | -10.27 |
| Weighted Avg Shares Out | 114.22M | 81.87M | 75.22M | 72.04M | 61.96M | 56.78M | 45.90M | 37.52M | 35.62M | 31.14M | 6.07M | 2.39M | 1.00M |
| Weighted Avg Shares Out (Dil) | 114.22M | 81.87M | 75.22M | 72.04M | 61.96M | 56.78M | 45.90M | 37.52M | 35.62M | 31.14M | 6.07M | 2.39M | 1.00M |
Karyopharm Therapeutics Provides Endometrial Cancer Program Update
NEWTON, Mass. , Dec. 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it is in discussions and has an upcoming meeting with the U.S. Food and Drug Administration (FDA)...
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass. , Dec. 2, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 4,800 restricted stock units (RSUs) to two newly-hired employees.
Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference
NEWTON, Mass. , Nov. 25, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Piper Sandler 36th Annual Healthcare Conference in a...
Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer
NEWTON, Mass. , Nov. 20, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Kristin Abate, the Company's Vice President, Accounting, Corporate Controller and Assistant Treasurer has been appointed the...
Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition
NEWTON, Mass. , Nov. 18, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced abstracts detailing selinexor data have been selected to be presented at the 66th American Society of Hematology (ASH)...
Karyopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call Transcript
Karyopharm Therapeutics Inc. (NASDAQ:KPTI ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Elhan Webb - Senior Vice President, Investor Relations Richard Paulson - President and Chief Executive Officer Reshma Rangwala - Chief Medical Officer...
Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024
SHANGHAI and HONG KONG , Nov. 5, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that it will...
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.30 per share a year ago.
Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
– Achieves Third Quarter 2024 Total Revenue of $38.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $29.5 Million; Continued Regulatory and Reimbursement Approvals Globally – – Following FDA Alignment, Absolute Change in Total Symptom Score (Abs-TSS) Will Replace TSS50...
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass. , Nov. 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 10,500 restricted stock units (RSUs) to three newly-hired employees.
Source: https://incomestatements.info
Category: Stock Reports